# Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-the-dipeptidyl-peptidase-4-inhibitor-sitagliptin-as/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Itamar Raz,M Hanefeld,Lei Xu,Cíntia Rabelo e Paiva Caria,Debora Williams‐Herman,Hootan Khatami,Sitagliptin Study 023 Group |
| Citations | 617 |
| DOI | 10.1007/s00125-006-0416-z |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://link.springer.com/content/pdf/10.1007/s00125-006-0416-z.pdf |
| OpenAlex ID | https://openalex.org/W2051462052 |
| PMID | 17001471 |
| Type | article |
| Year | 2006 |

## Paper authors

- [Itamar Raz](https://scholariq.org/researchers/itamar-raz/)

## Paper journal

- [Diabetologia](https://scholariq.org/journals/diabetologia/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.